Product Images Eslicarbazepine Acetate

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Eslicarbazepine Acetate NDC 43598-687 by Dr.reddys Laboratories Inc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

container1 - container1

container1 - container1

container2 - container2

container2 - container2

Not available.*

container3 - container3

container3 - container3

container4 - container4

container4 - container4

figure1 - figure1

figure1 - figure1

This text provides recommendations for dose adjustment based on factors such as age, gender, and hepatic impairment. It outlines specific instructions for different scenarios, including when dose adjustment is necessary and when it is not required. Additionally, it mentions the change due to fold change and 90% confidence interval, as well as a change relative to reference.*

figure2 - figure2

figure2 - figure2

figure3a - figure3a

figure3a - figure3a

This is a list of various anticonvulsant medications along with recommendations for adjustments based on clinical response and serum levels. It provides information on which drugs may need monitoring or dose adjustments and potential pharmacodynamic interactions.*

figure3b - figure3b

figure3b - figure3b

This text provides a list of drugs and their recommended adjustments. It includes information on changing doses based on observed lipid levels for simvastatin and rosuvastatin, the need for alternative birth control methods when using oral contraceptives in combination with certain medications, and the necessity of monitoring INR levels for patients on warfarin.*

figure4 - figure4

figure4 - figure4

figure5 - figure5

figure5 - figure5

The text provides information on the proportion of patients in specific percentage ranges (0 to <26%, 25 to <50%, 50 to <75%) and the corresponding reduction in seizure frequency from baseline (75-100%). This data can be used to analyze the effectiveness of a treatment or intervention on seizure reduction among patients.*

structure - structure

structure - structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.